Regulatory officials and Alzheimer’s researchers expressed concern over the efficacy of Alzheimer’s drug simufilam, developed by Cassava Sciences, The New York Times reported Oct. 3.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
